share_log

艾美疫苗：截至2024年6月30日止六個月之中期業績公告

AIM VACCINE: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEX ·  Aug 29, 2024 06:15

Summary by Moomoo AI

艾美疫苗股份有限公司公布截至2024年6月30日止六個月的中期業績，顯示收入輕微下降0.6%，毛利下降10.3%。期內虧損由上年同期的人民幣257.4百萬元減少至人民幣145.3百萬元，減少43.6%。研發支出減少57.3%，主要由於海外臨床試驗相關的研發支出減少。銷售及分銷開支輕微上升3.3%，行政開支增加7.4%。公司繼續推進新產品的研發，包括mRNA技術平台相關疫苗、肺炎在研疫苗及其他在研疫苗。公司亦積極開拓國際市場，已在多個國家開始註冊工作，並成功將疫苗出口至包括巴基斯坦和科特迪瓦等國。此外，公司加強疫苗全程溫度監測系列產品的推廣，提升產品競爭力。截至2024年6月30日，公司現金及現金等價物以及定期存款合計為人民幣655.3百萬元，流動負債淨額為人民幣433.2百萬元。
艾美疫苗股份有限公司公布截至2024年6月30日止六個月的中期業績，顯示收入輕微下降0.6%，毛利下降10.3%。期內虧損由上年同期的人民幣257.4百萬元減少至人民幣145.3百萬元，減少43.6%。研發支出減少57.3%，主要由於海外臨床試驗相關的研發支出減少。銷售及分銷開支輕微上升3.3%，行政開支增加7.4%。公司繼續推進新產品的研發，包括mRNA技術平台相關疫苗、肺炎在研疫苗及其他在研疫苗。公司亦積極開拓國際市場，已在多個國家開始註冊工作，並成功將疫苗出口至包括巴基斯坦和科特迪瓦等國。此外，公司加強疫苗全程溫度監測系列產品的推廣，提升產品競爭力。截至2024年6月30日，公司現金及現金等價物以及定期存款合計為人民幣655.3百萬元，流動負債淨額為人民幣433.2百萬元。
AIMMUNE Vaccine Co., Ltd. released the mid-year performance as of June 30, 2024, showing a slight decrease in revenue of 0.6% and a 10.3% decrease in gross profit. The loss for the period decreased by 43.6% from RMB 257.4 million in the same period of the previous year to RMB 145.3 million. The decrease was mainly due to reduced R&D expenses related to overseas clinical trials. Sales and distribution expenses increased by 3.3%, while administrative expenses increased by 7.4%. The company continues to advance the research and development of new products, including mRNA technology platform-related vaccines, pneumonia vaccines under development, and other vaccines under development. The company is also actively expanding into international markets, with registrations underway in multiple countries, and successful vaccine exports to countries...Show More
AIMMUNE Vaccine Co., Ltd. released the mid-year performance as of June 30, 2024, showing a slight decrease in revenue of 0.6% and a 10.3% decrease in gross profit. The loss for the period decreased by 43.6% from RMB 257.4 million in the same period of the previous year to RMB 145.3 million. The decrease was mainly due to reduced R&D expenses related to overseas clinical trials. Sales and distribution expenses increased by 3.3%, while administrative expenses increased by 7.4%. The company continues to advance the research and development of new products, including mRNA technology platform-related vaccines, pneumonia vaccines under development, and other vaccines under development. The company is also actively expanding into international markets, with registrations underway in multiple countries, and successful vaccine exports to countries including Pakistan and Côte d'Ivoire. In addition, the company has strengthened the promotion of products in the vaccine full-process temperature monitoring series to enhance product competitiveness. As of June 30, 2024, the company's cash and cash equivalents, as well as time deposits, totaled RMB 655.3 million, and the net current liabilities were RMB 433.2 million.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    ANTENGENE-B
    06996
    -- 3.290
    C HEALTH GP
    08225
    -- 0.179
    SINO BIOPHARM
    01177
    -- 3.560
    3SBIO
    01530
    -- 8.520
    HANSOH PHARMA
    03692
    -- 18.800
    Log In for the Full List
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
    Discussing
    As China's 'two sessions' commence: How will Chinese stocks perform?
    🎙️Discussion 1. With the government's emphasis on technological innovation and sustainability, which industry sectors do you believe hold t Show More
    China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings